PULSE BIOSCIENCES, INC.

Trading Arrangements

Except as noted below, during thenine-months ended* September 30, 2025*,none of our directors or officers (as defined in Rule16a-1(f) under the Exchange Act) adopted or terminated a “Rule10b5-1 trading arrangement” or a “non-Rule10b5-1 trading arrangement” as such terms are defined under Item408 of Regulation S-K.

On* May 14, 2025,Kevin Danahy, the Company’s Chief Commercial Officer, adopted a Rule10b5‑1* trading arrangement intended to satisfy the affirmative defense of Rule10b5-1(c) under the Exchange Act for the exercise of vested options and the sale of up to 150,000 shares of common stock between* August 13, 2025and May 1, 2026 (*the “Sales Period”), net of shares to satisfy withholding obligations, so long as the market price of the Company’s common stock during the Sales Period is higher than certain minimum thresholds specified in his trading plan.

On* June 12, 2025,Darrin Uecker, the Company’s Chief Technology Officer and a Director, adopted a Rule10b5‑1* trading arrangement intended to satisfy the affirmative defense of Rule10b5-1(c) under the Exchange Act for the exercise of expiring options and the sale of up to 120,000 shares of common stock between* September 11, 2025and September 20, 2025,*net of shares to satisfy withholding obligations, so long as the market price of the Company’s common stock during the Sales Period was higher than a certain minimum threshold specified in his trading plan.